Dale B. Schenk Net Worth

The estimated Net Worth of Dale B. Schenk is at least $698 Тысяча dollars as of 17 November 2015. Dale Schenk owns over 33,333 units of Prothena plc stock worth over $697,660 and over the last 12 years Dale sold PRTA stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Dale Schenk PRTA stock SEC Form 4 insiders trading

Dale has made over 3 trades of the Prothena plc stock since 2014, according to the Form 4 filled with the SEC. Most recently Dale exercised 33,333 units of PRTA stock worth $200,998 on 17 November 2015.

The largest trade Dale's ever made was exercising 33,333 units of Prothena plc stock on 17 November 2015 worth over $200,998. On average, Dale trades about 10,667 units every 79 days since 2013. As of 17 November 2015 Dale still owns at least 33,333 units of Prothena plc stock.

You can see the complete history of Dale Schenk stock trades at the bottom of the page.

What's Dale Schenk's mailing address?

Dale's mailing address filed with the SEC is C/O PROTHENA BIOSCIENCES INC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.

Insiders trading at Prothena plc

Over the last 12 years, insiders at Prothena plc have traded over $79,429,035 worth of Prothena plc stock and bought 2,987,732 units worth $75,619,043 . The most active insiders traders include Capital, Llc Eco R1, Co Plc Elan Corp Plc Elan S... и Helen Susan Kim. On average, Prothena plc executives and independent directors trade stock every 21 days with the average trade being worth of $946,769. The most recent stock trade was executed by Karin L Walker on 24 January 2024, trading 5,000 units of PRTA stock currently worth $67,650.

What does Prothena plc do?

prothena corporation plc (nasdaq: prta) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. the company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications, including al amyloidosis (neod001), parkinson’s disease and other related synucleinopathies (prx002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (prx003). our lead program, neod001, is in a global phase 3 registration clinical trial – the vital amyloidosis study. there is also an on-going phase 1/2 trial. prx002 is in a phase 1 multiple ascending dose clinical trial, and prx003 is in a phase 1 single ascending dose clinical trial. prothena’s elite team has a recognized track record both f

Complete history of Dale Schenk stock trades at Prothena plc

Prothena plc executives and stock owners

Prothena plc executives and other stock owners filed with the SEC include:

• Wagner Zago,
  Chief Scientific Officer
• Gene Kinney,
  President, Chief Executive Officer, Director
• Michael Malecek,
  Chief Legal Officer and Company Secretary
• Tran Nguyen,
  Chief Financial Officer, Chief Operating Officer
• Carol Karp,
  Chief Regulatory Officer
• Radhika Tripuraneni,
  Chief Development Officer
• Dr. Gene G. Kinney Ph.D.,
  Pres, CEO & Director
• Dr. Hideki Garren M.D., Ph.D.,
  Chief Medical Officer
• Tran B. Nguyen M.B.A.,
  CFO & Chief Strategy Officer
• Carol D. Karp,
  Chief Regulatory Officer
• Michael J. Malecek,
  Chief Legal Officer & Company Sec.
• Brandon S. Smith,
  Chief Operating Officer
• Paula Cobb,
  Independent Director
• Lars Ekman,
  Independent Chairman of the Board
• Dennis Selkoe,
  Independent Director
• Shane Cooke,
  Independent Director
• Richard Collier,
  Independent Director
• Christopher Henney,
  Independent Director
• K. Anders Harfstrand,
  Independent Director
• Brandon Smith,
  Chief Business Officer
• Oleg Nodelman,
  Independent Director
• Karin Walker,
  Chief Accounting Officer, Controller
• Dr. Radhika Tripuraneni M.D., M.P.H.,
  Chief Devel. Officer
• Dr. Hideki Garren,
  Chief Medical Officer
• Dr. Radhika Tripuraneni M.P.H., M.D.,
  Chief Devel. Officer
• Jennifer Zibuda,
  Director of Investor Relations & Communication
• Dr. Wagner M. Zago,
  Chief Scientific Officer
• Karin L. Walker CPA, CPA,
  Chief Accounting Officer & Controller
• Sarah B. Noonberg,
  Chief Medical Officer
• Arthur W Homan,
  Chief Legal Officer
• Tara Nickerson,
  Chief Business Officer
• Martin Koller,
  Chief Medical Officer
• Capital, Llc Eco R1,
  10% owner
• Sanjiv Patel,
  
• Co Plc Elan Corp Plc Elan S...,
  
• Dale B. Schenk,
  President and CEO
• John Randall Fawcett,
  Controller
• David B. Mc Ninch,
  Chief Commercial Officer
• William H. Jr. Dunn,
  
• Helen Susan Kim,
  
• Daniel G Welch,
  
• Hideki Garren,
  Chief Medical Officer
• David A Ford,
  Chief People Officer